

Walter Ageno

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3316358/publications.pdf>

Version: 2024-02-01

510
papers

31,550
citations

9264

74
h-index

5539

163
g-index

522
all docs

522
docs citations

522
times ranked

26558
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune-Mediated Mechanisms in Patients Testing Positive for SARS-CoV-2: Protocol for a Multianalysis Study. <i>JMIR Research Protocols</i> , 2022, 11, e29892.	1.0	1
2	Profile of Patients with Isolated Distal Deep Vein Thrombosis versus Proximal Deep Vein Thrombosis or Pulmonary Embolism: RE-COVERY DVT/PE Study. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 446-458.	2.7	15
3	Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1248-1263.	1.8	40
4	Safety and effectiveness of dabigatran in routine clinical practice: the RE-COVERY DVT/PE study. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 399-409.	2.1	3
5	Estimating Bleeding Risk in Patients with Cancer-Associated Thrombosis: Evaluation of Existing Risk Scores and Development of a New Risk Score. <i>Thrombosis and Haemostasis</i> , 2022, 122, 818-829.	3.4	23
6	Reduced-Dose Intravenous Thrombolysis for Acute Intermediate- to High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International Thrombolysis (PEITHO)-3 trial. <i>Thrombosis and Haemostasis</i> , 2022, 122, 857-866.	3.4	35
7	Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society. <i>European Heart Journal</i> , 2022, 43, 182-189.	2.2	83
8	Splanchnic vein thrombosis-related mortality in the Veneto region (Italy), 2008-2019: Retrospective analysis of epidemiological data. <i>Thrombosis Research</i> , 2022, 209, 41-46.	1.7	3
9	An update on the global use of risk assessment models and thromboprophylaxis in hospitalized patients with medical illnesses from the World Thrombosis Day steering committee: Systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 409-421.	3.8	17
10	Current practices of standardized risk assessment for venous thromboembolism: Results from a global survey from the World Thrombosis Day steering committee. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 532-535.	3.8	7
11	Anticoagulant treatment for upper extremity deep vein thrombosis: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 661-670.	3.8	11
12	Low in-hospital mortality rate in patients with COVID-19 receiving thromboprophylaxis: data from the multicentre observational START-COVID Register. <i>Internal and Emergency Medicine</i> , 2022, , 1.	2.0	11
13	Cerebral venous thrombosis. <i>Minerva Medica</i> , 2022, 112, .	0.9	6
14	Treatment of portal vein thrombosis: an updated narrative review. <i>Minerva Medica</i> , 2022, 112, .	0.9	7
15	Treatment of Atypical Clots. <i>Hamostaseologie</i> , 2022, 42, 010-018.	1.9	0
16	Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials. <i>Circulation</i> , 2022, 145, 1471-1479.	1.6	6
17	Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study. <i>Blood Advances</i> , 2022, 6, 3569-3578.	5.2	19
18	Antithrombotic treatment of retinal vein occlusion: a position statement from the Italian Society on Thrombosis and Haemostasis (SISET).. <i>Blood Transfusion</i> , 2022, , .	0.4	2

#	ARTICLE	IF	CITATIONS
19	Rationale and design of a study on D-dimer use to stratify patients after a first unprovoked venous thromboembolism for their risk of recurrence: extended low-dose Apixaban given only to patients with positive D-dimer results. , 2022, 1, 38-44.		0
20	Recurrent Ischemic Stroke and Bleeding in Patients With Atrial Fibrillation Who Suffered an Acute Stroke While on Treatment With Nonvitamin K Antagonist Oral Anticoagulants: The RENO-EXTEND Study. Stroke, 2022, 53, 2620-2627.	2.0	28
21	Investigational drugs for ischemic stroke: whatâ€™s in the clinical development pipeline for acute phase and prevention?. Expert Opinion on Investigational Drugs, 2022, , 1-23.	4.1	1
22	Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis. Blood Advances, 2022, 6, 4516-4523.	5.2	16
23	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. JAMA Cardiology, 2022, 7, 747.	6.1	15
24	Thromboembolic Complications in COVID-19 Patients Hospitalized in Italian Ordinary Wards: Data from the Multicenter Observational START-COVID Register. TH Open, 2022, 06, e251-e256.	1.4	2
25	Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial. TH Open, 2022, 06, e177-e183.	1.4	1
26	Design and rationale of a randomized, placebo-controlled trial on the efficacy and safety of sulodexide for extended treatment in elderly patients after a first venous thromboembolism. Internal and Emergency Medicine, 2021, 16, 359-368.	2.0	3
27	Follow-up management of patients receiving direct oral anticoagulants. Internal and Emergency Medicine, 2021, 16, 571-580.	2.0	2
28	Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000â€“18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database. Lancet Respiratory Medicine, 2021, 9, 33-42.	10.7	100
29	Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. Thrombosis and Haemostasis, 2021, 121, 616-624.	3.4	55
30	Clinical history of cancer-associated splanchnic vein thrombosis. Journal of Thrombosis and Haemostasis, 2021, 19, 983-991.	3.8	12
31	Safety and effectiveness of biosimilar enoxaparin (Inhixa) for the prevention of thromboembolism in medical and surgical inpatients. Internal and Emergency Medicine, 2021, 16, 933-939.	2.0	1
32	Survival and quality of life after early discharge in low-risk pulmonary embolism. European Respiratory Journal, 2021, 57, 2002368.	6.7	17
33	Profile of patients diagnosed with acute venous thromboembolism in routine practice according to age and renal function: RE-COVERY DVT/PE study. Journal of Thrombosis and Thrombolysis, 2021, 51, 561-570.	2.1	0
34	Does Chronic Treatment with Oral Anticoagulants Ameliorate the Clinical Course of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Coronavirus Disease 2019 (COVID-19)?. Seminars in Thrombosis and Hemostasis, 2021, 47, 338-340.	2.7	13
35	Anticoagulant therapy for splanchnic vein thrombosis: a systematic review and meta-analysis. Blood, 2021, 137, 1233-1240.	1.4	42
36	Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE. TH Open, 2021, 05, e24-e34.	1.4	16

#	ARTICLE	IF	CITATIONS
37	Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1054-1065.	3.4	87
38	Direct oral anticoagulants for unusual site venous thromboembolism. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 265-277.	2.3	14
39	Clinical risk scores for the early prediction of severe outcomes in patients hospitalized for COVID-19. <i>Internal and Emergency Medicine</i> , 2021, 16, 989-996.	2.0	15
40	Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD-VTE. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 326-341.	2.3	23
41	Anticoagulant Treatment for Splanchnic Vein Thrombosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2021, 121, 867-876.	3.4	28
42	The effect of DOACs on several oral and parenteral anticoagulants. <i>International Journal of Laboratory Hematology</i> , 2021, 43, O171-O175.	1.3	9
43	Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA-LEA noninterventional studies. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 426-438.	2.3	10
44	Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: results from the SIMI-COVID-19 study of the Italian Society of Internal Medicine (SIMI). <i>Internal and Emergency Medicine</i> , 2021, 16, 1005-1015.	2.0	37
45	Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. <i>Stroke</i> , 2021, 52, 1450-1454.	2.0	7
46	Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE. <i>Thrombosis Research</i> , 2021, 201, 63-72.	1.7	14
47	SARS-CoV-2 B.1.1.7 reinfection after previous COVID-19 in two immunocompetent Italian patients. <i>Journal of Medical Virology</i> , 2021, 93, 5648-5649.	5.0	11
48	SARS-CoV-2 Vaccine and Thrombosis: An Expert Consensus on Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2021, 121, 982-991.	3.4	50
49	Association of thromboelastography profile with severity of liver cirrhosis and portal venous system thrombosis. <i>BMC Gastroenterology</i> , 2021, 21, 253.	2.0	9
50	Cancer-Associated Splanchnic Vein Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 931-941.	2.7	8
51	Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study. <i>Frontiers in Medicine</i> , 2021, 8, 639970.	2.6	20
52	Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering. <i>Journal of Healthcare Engineering</i> , 2021, 2021, 1-10.	1.9	2
53	Association between body mass index, waist circumference, and relative fat mass with the risk of first unprovoked venous thromboembolism. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 3122-3130.	2.6	7
54	Outcomes among patients with cancer and incidental or symptomatic venous thromboembolism: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2468-2479.	3.8	21

#	ARTICLE	IF	CITATIONS
55	Difficult challenges in vascular medicine. <i>Minerva Medica</i> , 2021, , .	0.9	0
56	The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE. <i>Thrombosis Research</i> , 2021, 203, 155-162.	1.7	9
57	Protective effect of oral anticoagulant drugs in atrial fibrillation patients admitted for COVID-19: Results from the CORIST study. <i>Thrombosis Research</i> , 2021, 203, 138-141.	1.7	5
58	Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2801-2813.	3.8	19
59	Recurrent bleeding and thrombotic events after resumption of oral anticoagulants following gastrointestinal bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2618-2628.	3.8	12
60	Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2772-2780.	3.8	4
61	Incidence Rates and Case-Fatality Rates of Cerebral Vein Thrombosis: A Population-Based Study. <i>Stroke</i> , 2021, 52, 3578-3585.	2.0	9
62	Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism. <i>Annals of Internal Medicine</i> , 2021, 174, 1420-1429.	3.9	60
63	Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial. <i>Lancet Haematology</i> , 2021, 8, e627-e636.	4.6	11
64	Influence of body mass index on clinical outcomes in venous thromboembolism: Insights from GARFIELD-VTE. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3031-3043.	3.8	14
65	Introduction of SARS-CoV-2 variant of concern 20h/501Y.V2 (B.1.351) from Malawi to Italy. <i>Emerging Microbes and Infections</i> , 2021, 10, 710-712.	6.5	7
66	Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD-VTE. <i>Journal of Thrombosis and Haemostasis</i> , 2021, , .	3.8	8
67	Heparin induced thrombocytopenia: position paper from the Italian Society on Thrombosis and Haemostasis (SISET). <i>Blood Transfusion</i> , 2021, 19, 14-23.	0.4	4
68	Treatment of Portal, Mesenteric, and Splenic Vein Thrombosis with Rivaroxaban: A Pilot, Prospective Cohort Study. <i>Blood</i> , 2021, 138, 671-671.	1.4	1
69	Milvexian for the Prevention of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2021, 385, 2161-2172.	27.0	122
70	Do women with venous thromboembolism bleed more than men during anticoagulation? Data from the real-life, prospective START-Register. <i>Therapeutic Advances in Drug Safety</i> , 2021, 12, 204209862110629.	2.4	5
71	Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial. <i>European Heart Journal</i> , 2020, 41, 509-518.	2.2	106
72	Trends in mortality related to pulmonary embolism in the European Region, 2000-2015: analysis of vital registration data from the WHO Mortality Database. <i>Lancet Respiratory Medicine</i> , 2020, 8, 277-287.	10.7	192

#	ARTICLE	IF	CITATIONS
73	Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 214-219.	2.1	6
74	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>European Heart Journal</i> , 2020, 41, 543-603.	2.2	2,426
75	D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study. <i>Internal and Emergency Medicine</i> , 2020, 15, 453-462.	2.0	10
76	The risk of post-thrombotic syndrome in patients with proximal deep vein thrombosis treated with the direct oral anticoagulants. <i>Internal and Emergency Medicine</i> , 2020, 15, 447-452.	2.0	28
77	American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. <i>Blood Advances</i> , 2020, 4, 4693-4738.	5.2	636
78	Anticoagulation control with the point-of-care INR: A retrospective pre-/post-analysis. <i>Thrombosis Research</i> , 2020, 196, 21-24.	1.7	0
79	Prediction of venous thromboembolism in patients with lower-limb immobilization. <i>EClinicalMedicine</i> , 2020, 21, 100285.	7.1	0
80	PREvention of VENous Thromboembolism in Hemorrhagic Stroke Patients " PREVENTIHS Study: A Randomized Controlled Trial and a Systematic Review and Meta-Analysis. <i>European Neurology</i> , 2020, 83, 566-575.	1.4	5
81	Magnetic Resonance Thrombus Imaging to Differentiate Acute from Chronic Portal Vein Thrombosis. <i>TH Open</i> , 2020, 04, e224-e230.	1.4	6
82	Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register. <i>BMJ Open</i> , 2020, 10, e040449.	1.9	11
83	Timing of initiation of oral anticoagulants in patients with acute ischemic stroke and atrial fibrillation comparing posterior and anterior circulation strokes. <i>European Stroke Journal</i> , 2020, 5, 374-383.	5.5	6
84	Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1899-1913.	2.6	137
85	Anticoagulation in splanchnic and cerebral vein thrombosis: An international vignette-based survey. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 1192-1202.	2.3	10
86	Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease. <i>JAMA Network Open</i> , 2020, 3, e2022886.	5.9	28
87	Rivaroxaban for the treatment of venous thromboembolism in pediatric patients. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 733-741.	1.5	8
88	Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. <i>Lancet Haematology</i> , 2020, 7, e746-e755.	4.6	21
89	Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study. <i>European Journal of Internal Medicine</i> , 2020, 82, 38-47.	2.2	88
90	Coagulation parameters and venous thromboembolism in patients with and without COVID-19 admitted to the Emergency Department for acute respiratory insufficiency. <i>Thrombosis Research</i> , 2020, 196, 209-212.	1.7	16

#	ARTICLE	IF	CITATIONS
91	Sex-related characteristics of cerebral vein thrombosis: A secondary analysis of a multicenter international cohort study. <i>Thrombosis Research</i> , 2020, 196, 371-374.	1.7	3
92	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1004-1024.	3.4	206
93	Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1859-1865.	3.8	547
94	Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. <i>Journal of the American College of Cardiology</i> , 2020, 75, 3140-3147.	2.8	50
95	Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. Perspective. <i>Thrombosis and Haemostasis</i> , 2020, 120, 924-936.	3.4	12
96	Recurrence of immune thrombocytopenia at the time of SARS-CoV-2 infection. <i>Annals of Hematology</i> , 2020, 99, 1951-1952.	1.8	14
97	Cerebral and Splanchnic Vein Thrombosis: Advances, Challenges, and Unanswered Questions. <i>Journal of Clinical Medicine</i> , 2020, 9, 743.	2.4	20
98	Rapid Salivary Test suitable for a mass screening program to detect SARS-CoV-2: A diagnostic accuracy study. <i>Journal of Infection</i> , 2020, 81, e75-e78.	3.3	67
99	Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 267-277.	2.1	54
100	Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE. <i>Thrombosis Research</i> , 2020, 191, 103-112.	1.7	22
101	Hospital-based use of thromboprophylaxis in patients with COVID-19. <i>Lancet, The</i> , 2020, 395, e75.	13.7	40
102	The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1940-1951.	3.8	60
103	Risk of intracranial bleeding in patients with primary brain cancer receiving therapeutic anticoagulation for venous thromboembolism: A meta-analysis. <i>Brain and Behavior</i> , 2020, 10, e01638.	2.2	30
104	The safety of anticoagulant therapy in the treatment of splanchnic vein thrombosis associated with acute pancreatitis. <i>Internal and Emergency Medicine</i> , 2020, 15, 929-931.	2.0	1
105	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2950-2973.	2.8	2,392
106	Anticoagulant therapy for splanchnic vein thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1562-1568.	3.8	60
107	Thrombolytics for venous thromboembolic events: a systematic review with meta-analysis. <i>Blood Advances</i> , 2020, 4, 1539-1553.	5.2	15
108	Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE Study. <i>American Journal of Medicine</i> , 2020, 133, 936-945.	1.5	10

#	ARTICLE	IF	CITATIONS
109	Hypercoagulopathy in Severe COVID-19: Implications for Acute Care. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1654-1667.	3.4	25
110	COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). <i>Blood Transfusion</i> , 2020, 18, 167-169.	0.4	247
111	Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study. <i>Blood Transfusion</i> , 2020, 18, 486-495.	0.4	5
112	Epidemiology of Budd-Chiari Syndrome. , 2020, , 15-25.		1
113	A survey on the views and attitudes of Italian physicians regarding the prophylaxis and treatment of venous thromboembolism. <i>Minerva Medica</i> , 2020, 111, 370-372.	0.9	0
114	Patients' satisfaction associated with portable coagulometers for warfarin monitoring: a cross-sectional study. <i>Blood Transfusion</i> , 2020, 18, 386-395.	0.4	0
115	Early recurrence in paroxysmal versus sustained atrial fibrillation in patients with acute ischaemic stroke. <i>European Stroke Journal</i> , 2019, 4, 55-64.	5.5	4
116	Net clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2089-2098.	3.8	5
117	Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1675-1685.	3.4	34
118	D-dimer levels during and after anticoagulation withdrawal in patients with venous thromboembolism treated with non-vitamin K anticoagulants. <i>PLoS ONE</i> , 2019, 14, e0219751.	2.5	10
119	Reliability and validity of the Maltese version of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q). <i>Patient Preference and Adherence</i> , 2019, Volume 13, 969-979.	1.8	7
120	Patient Management Strategies and Long-Term Outcomes in Isolated Distal Deep-Vein Thrombosis versus Proximal Deep-Vein Thrombosis: Findings from XALIA. <i>TH Open</i> , 2019, 03, e85-e93.	1.4	20
121	Validation and psychometric properties of the Maltese version of the Duke Anticoagulation Satisfaction Scale (DASS). <i>Psychology Research and Behavior Management</i> , 2019, Volume 12, 741-752.	2.8	7
122	Splanchnic Vein Thrombosis: Current Perspectives. <i>Vascular Health and Risk Management</i> , 2019, Volume 15, 449-461.	2.3	74
123	2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Lancet Oncology</i> , The, 2019, 20, e566-e581.	10.7	458
124	Very elderly patients with venous thromboembolism on oral anticoagulation with VKAs or DOACs: Results from the prospective multicenter START2-Register Study. <i>Thrombosis Research</i> , 2019, 183, 28-32.	1.7	13
125	Oral anticoagulation in very elderly patients with atrial fibrillation: Results from the prospective multicenter START2-REGISTER study. <i>PLoS ONE</i> , 2019, 14, e0216831.	2.5	19
126	Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1694-1706.	3.8	30

#	ARTICLE	IF	CITATIONS
127	Anticoagulation After Stroke in Patients With Atrial Fibrillation. <i>Stroke</i> , 2019, 50, 2093-2100.	2.0	29
128	Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. <i>Stroke</i> , 2019, 50, 2168-2174.	2.0	59
129	Epidemiology and secondary prevention of ischemic stroke in patients on antiplatelet drug: a retrospective cohort study. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 336-344.	2.1	9
130	Treatment of venous thromboembolism with tinzaparin in oncological patients. <i>Minerva Medica</i> , 2019, 110, 251-258.	0.9	6
131	Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1365-1372.	3.4	28
132	The management of anticoagulant treatment in non-valvular atrial fibrillation real-world patients. <i>European Journal of Internal Medicine</i> , 2019, 62, 7-8.	2.2	0
133	XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America. <i>Thrombosis Research</i> , 2019, 176, 125-132.	1.7	17
134	Portal Vein Thrombosis in Decompensated Cirrhosis: Rationale for Treatment. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00026.	2.5	6
135	The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section "Special Situations". <i>Thrombosis and Haemostasis</i> , 2019, 119, 014-038.	3.4	28
136	Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 319-327.	3.4	76
137	Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis. <i>European Journal of Internal Medicine</i> , 2019, 61, 29-33.	2.2	3
138	Increased Risk of Death in Acutely Ill Medical Patients with Asymptomatic Proximal Deep Vein Thrombosis or Symptomatic Venous Thromboembolism: Insights from the Magellan Study. <i>Blood</i> , 2019, 134, 163-163.	1.4	8
139	Association of Bleeding Severity with Mortality with in-Hospital and Extended Thromboprophylaxis in the Medically Ill in the Magellan Trial. <i>Blood</i> , 2019, 134, 2441-2441.	1.4	0
140	Position paper on laboratory testing for patients with haemophilia. A consensus document from SISET, AICE, SIBioC and SIPMeL. <i>Blood Transfusion</i> , 2019, 17, 229-236.	0.4	10
141	Prognostic role of neutrophils to lymphocytes ratio in patients with acute pulmonary embolism: a systematic review and meta-analysis of the literature. <i>Internal and Emergency Medicine</i> , 2018, 13, 603-608.	2.0	26
142	Outcomes during anticoagulation in patients with symptomatic vs. incidental splanchnic vein thrombosis. <i>Thrombosis Research</i> , 2018, 164, 69-74.	1.7	35
143	Multiple overlapping systematic reviews facilitate the origin of disputes: the case of thrombolytic therapy for pulmonary embolism. <i>Journal of Clinical Epidemiology</i> , 2018, 97, 1-13.	5.0	25
144	Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial. <i>Thrombosis Research</i> , 2018, 162, 7-14.	1.7	20

#	ARTICLE	IF	CITATIONS
145	Initial strides for invent-VTE: Towards global collaboration to accelerate clinical research in venous thromboembolism. <i>Thrombosis Research</i> , 2018, 163, 128-131.	1.7	4
146	Cancer-associated ischemic stroke: A retrospective multicentre cohort study. <i>Thrombosis Research</i> , 2018, 165, 33-37.	1.7	45
147	Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent. <i>TH Open</i> , 2018, 02, e1-e7.	1.4	5
148	Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. <i>European Heart Journal</i> , 2018, 39, 4208-4218.	2.2	267
149	Clinical manifestations and imaging tools in the diagnosis of splanchnic and cerebral vein thromboses. <i>Thrombosis Research</i> , 2018, 163, 252-259.	1.7	24
150	Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients? Yes. <i>Internal and Emergency Medicine</i> , 2018, 13, 1009-1013.	2.0	3
151	Breadth of complications of long-term oral anticoagulant care. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 432-438.	2.5	12
152	Patient-Reported Treatment Experience with Oral Rivaroxaban: Results from the Noninterventional XALIA Study of Deep-Vein Thrombosis. <i>TH Open</i> , 2018, 02, e139-e146.	1.4	5
153	Initial and Long-Term Treatment of Pulmonary Embolism: Current Approach and Future Perspectives. <i>Hamostaseologie</i> , 2018, 38, 75-86.	1.9	2
154	Hemorrhagic Transformation in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Time to Initiation of Oral Anticoagulant Therapy and Outcomes. <i>Journal of the American Heart Association</i> , 2018, 7, e010133.	3.7	55
155	Risk of bleeding and arterial cardiovascular events in patients with splanchnic vein thrombosis in Denmark: a population-based cohort study. <i>Lancet Haematology</i> , 2018, 5, e441-e449.	4.6	17
156	Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry. <i>Internal and Emergency Medicine</i> , 2018, 13, 1051-1058.	2.0	25
157	Estimating renal function in patients with atrial fibrillation: which dose of direct oral anticoagulants?. <i>Internal and Emergency Medicine</i> , 2018, 13, 1001-1004.	2.0	3
158	Antithrombotic therapy for venous thromboembolism in patients with cancer: expert guidance. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1177-1185.	1.8	12
159	Antithrombotic therapy for patients with an indication for oral anticoagulation undergoing percutaneous coronary intervention with stent: The case of venous thromboembolism. <i>International Journal of Cardiology</i> , 2018, 269, 75-79.	1.7	4
160	Reducing the burden of venous thromboembolism in the acute medically ill population with extended-duration thromboprophylaxis. <i>European Heart Journal Supplements</i> , 2018, 20, E6-E11.	0.1	4
161	Biomarkers for the diagnosis of venous thromboembolism: D-dimer, thrombin generation, procoagulant phospholipid and soluble P-selectin. <i>Journal of Clinical Pathology</i> , 2018, 71, 1015-1022.	2.0	18
162	Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. <i>New England Journal of Medicine</i> , 2018, 379, 1118-1127.	27.0	205

#	ARTICLE	IF	CITATIONS
163	Timing of anticoagulation for portal vein thrombosis in liver cirrhosis: An Italian internist's perspective. <i>Journal of Translational Internal Medicine</i> , 2018, 6, 6-10.	2.5	3
164	Long-Term Outcome of Splanchnic Vein Thrombosis in Cirrhosis. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e176.	2.5	57
165	Predictive value of venous thromboembolism (<sc>VTE</sc>)â€‹<sc>BLEED</sc> to predict major bleeding and other adverse events in a practiceâ€‹based cohort of patients with <sc>VTE</sc>: results of the <sc>XALIA</sc> study. <i>British Journal of Haematology</i> , 2018, 183, 457-465.	2.5	32
166	Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the Siset, FCSA, SIBioC and SIPMeL. <i>Blood Transfusion</i> , 2018, 16, 462-470.	0.4	54
167	Edoxaban in Atrial Fibrillation and Venous Thromboembolismâ€‹”Ten Key Questions and Answers: A Practical Guide. <i>Advances in Therapy</i> , 2017, 34, 620-637.	2.9	8
168	Direct oral anticoagulants for superficial-vein thrombosis. <i>Lancet Haematology</i> , 2017, 4, e95-e96.	4.6	2
169	Prestroke CHA2DS2-VASc Score and Severity of Acute Stroke in Patients with Atrial Fibrillation: Findings from RAF Study. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2017, 26, 1363-1368.	1.6	7
170	Prediction of Early Recurrent Thromboembolic Event and Major Bleeding in Patients With Acute Stroke and Atrial Fibrillation by a Risk Stratification Schema. <i>Stroke</i> , 2017, 48, 726-732.	2.0	32
171	Italian intersociety consensus on DOAC use in internal medicine. <i>Internal and Emergency Medicine</i> , 2017, 12, 387-406.	2.0	44
172	Diagnostic accuracy of magnetic resonance imaging in patients with suspected pulmonary embolism: A bivariate meta-analysis. <i>Thrombosis Research</i> , 2017, 154, 64-72.	1.7	11
173	The prevention and treatment of venous thromboembolism in pregnancy. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 397-402.	1.5	24
174	Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study. <i>Thrombosis Research</i> , 2017, 155, 23-27.	1.7	9
175	Sex-related differences in risk factors, type of treatment received and outcomes in patients with atrial fibrillation and acute stroke: Results from the RAF-study (Early Recurrence and Cerebral Bleeding in) Tj ETQq1 1 0.784314 rgBT /Overl	1.7	11
176	An unusual case of neck pain in Hashimoto's thyroiditis. <i>Internal and Emergency Medicine</i> , 2017, 12, 817-819.	2.0	2
177	Pulmonary embolism prognostic factors and length of hospital stay: A cohort study. <i>Thrombosis Research</i> , 2017, 156, 155-159.	1.7	11
178	Impact of residual pulmonary obstruction on the long-term outcome of patients with pulmonary embolism. <i>European Respiratory Journal</i> , 2017, 49, 1601980.	6.7	89
179	Recanalization rate in patients with proximal vein thrombosis treated with the direct oral anticoagulants. <i>Thrombosis Research</i> , 2017, 153, 97-100.	1.7	31
180	Emerging therapeutic uses of direct-acting oral anticoagulants: An evidence-based perspective. <i>Pharmacological Research</i> , 2017, 120, 206-218.	7.1	11

#	ARTICLE	IF	CITATIONS
181	Clinical conundrums in antithrombotic therapy management: A Delphi Consensus panel. International Journal of Cardiology, 2017, 249, 249-256.	1.7	12
182	Data from a multidisciplinary poll of 178 expert physicians on the usage of non-vitamin K Oral Anticoagulants in patients with atrial fibrillation and venous thromboembolism. Data in Brief, 2017, 15, 532-539.	1.0	1
183	Direct oral anticoagulants for the treatment of acute venous thromboembolism in patients with cancer: a meta-analysis of randomised controlled trials. European Respiratory Journal, 2017, 50, 1701097.	6.7	15
184	Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTE. TH Open, 2017, 01, e33-e42.	1.4	18
185	Long-term recurrence of venous thromboembolism after short-term treatment of symptomatic isolated distal deep vein thrombosis: A cohort study. Vascular Medicine, 2017, 22, 518-524.	1.5	27
186	Evolving cardiovascular uses of direct-acting oral anticoagulants: a paradigm shift on the horizon?. Internal and Emergency Medicine, 2017, 12, 923-934.	2.0	4
187	Once- versus twice-daily direct oral anticoagulants in non-valvular atrial fibrillation. Expert Opinion on Pharmacotherapy, 2017, 18, 1325-1332.	1.8	23
188	Approach to thrombosis at unusual sites: Splanchnic and cerebral vein thrombosis. Vascular Medicine, 2017, 22, 529-540.	1.5	10
189	Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin K Oral Anticoagulants (RAFOACs) Study. Journal of the American Heart Association, 2017, 6, .	3.7	89
190	Chronobiologic Aspects of Venous Thromboembolism. Heart Failure Clinics, 2017, 13, 691-696.	2.1	11
191	Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome. Thrombosis and Haemostasis, 2017, 117, 794-800.	3.4	85
192	Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study. Thrombosis and Haemostasis, 2017, 117, 2425-2434.	3.4	9
193	ANMCO Position Paper: long-term follow-up of patients with pulmonary thromboembolism. European Heart Journal Supplements, 2017, 19, D309-D332.	0.1	10
194	Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. Thrombosis and Haemostasis, 2017, 117, 2406-2414.	3.4	8
195	NOACs for treatment of venous thromboembolism in clinical practice. Thrombosis and Haemostasis, 2017, 117, 1317-1325.	3.4	18
196	Therapeutic Shifts in the Management of Cancer-Associated Thrombosis. Thrombosis and Haemostasis, 2017, 117, 2012-2012.	3.4	0
197	Venous thromboembolism: Past, present and future. Thrombosis and Haemostasis, 2017, 117, 1219-1229.	3.4	88
198	Challenges in patients with splanchnic vein thrombosis. AME Medical Journal, 2017, 2, 104-104.	0.4	0

#	ARTICLE	IF	CITATIONS
199	RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate. <i>Thrombosis and Haemostasis</i> , 2017, 117, 415-421.	3.4	14
200	An Individual Participant Data Meta-Analysis of 13 Randomized Trials to Evaluate the Impact of Prophylactic Use of Heparin in Oncological Patients. <i>Blood</i> , 2017, 130, 626-626.	1.4	4
201	The Khorana Score for the Prediction of Venous Thromboembolism in Patients with Solid Cancer: An Individual Patient Data Meta-Analysis. <i>Blood</i> , 2017, 130, 627-627.	1.4	3
202	In vitro effects of Apixaban on 5 different cancer cell lines. <i>PLoS ONE</i> , 2017, 12, e0185035.	2.5	13
203	Managing reversal of direct oral anticoagulants in emergency situations. <i>Thrombosis and Haemostasis</i> , 2016, 116, 1003-1010.	3.4	39
204	Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy. <i>Thrombosis and Haemostasis</i> , 2016, 115, 399-405.	3.4	85
205	Spotlight on real-world evidence for the treatment of DVT: XALIA. <i>Thrombosis and Haemostasis</i> , 2016, 116, S41-S49.	3.4	5
206	The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. <i>Thrombosis and Haemostasis</i> , 2016, 115, 1240-1248.	3.4	64
207	Global Anticoagulant Registry in the Field “ Venous Thromboembolism (GARFIELD-VTE). <i>Thrombosis and Haemostasis</i> , 2016, 116, 1172-1179.	3.4	46
208	Dabigatran in clinical practice: Contemporary overview of the evidence. <i>International Journal of Cardiology</i> , 2016, 220, 417-428.	1.7	9
209	Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol. <i>BMJ Open</i> , 2016, 6, e010569.	1.9	18
210	Effect of Vitamin K Intake on the Stability of Treatment with Vitamin K Antagonists: A Systematic Review of the Literature. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 671-681.	2.7	7
211	In-hospital mortality due to pulmonary embolism in patients with Alzheimer disease: a sex effect?. <i>American Journal of Emergency Medicine</i> , 2016, 34, 665-666.	1.6	2
212	Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry. <i>Lancet Haematology</i> , 2016, 3, e267-e275.	4.6	55
213	Effect of thromboprophylaxis with anticoagulant drugs on the incidence of arterial thrombotic events in medical inpatients: a systematic review. <i>Internal and Emergency Medicine</i> , 2016, 11, 467-476.	2.0	1
214	Relationship between regulatory T cells subsets and lipid profile in dyslipidemic patients: a longitudinal study during atorvastatin treatment. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 26.	1.7	21
215	Management of recurrent venous thromboembolism in cancer patients. <i>Thrombosis Research</i> , 2016, 140, S128-S131.	1.7	11
216	Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. <i>Lancet Haematology</i> , 2016, 3, e437-e445.	4.6	29

#	ARTICLE	IF	CITATIONS
217	Riskâ€“Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies. <i>Drug Safety</i> , 2016, 39, 1175-1187.	3.2	31
218	Use of the Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 1035-1051.	2.2	8
219	Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2016, 116, 747-753.	3.4	28
220	Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2016, 116, 410-416.	3.4	39
221	Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists. <i>Thrombosis and Haemostasis</i> , 2016, 115, 424-432.	3.4	45
222	Real life studies and good clinical practice â€“ Authors' reply. <i>Lancet Haematology,the</i> , 2016, 3, e160-e161.	4.6	1
223	Guidance for the management of venous thrombosis in unusual sites. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 129-143.	2.1	87
224	Prognostic value of trans-thoracic echocardiography in patients with acute stroke and atrial fibrillation: findings from the RAF study. <i>Journal of Neurology</i> , 2016, 263, 231-237.	3.6	32
225	Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. <i>Lancet Haematology,the</i> , 2016, 3, e12-e21.	4.6	215
226	Nadroparin for the prevention of venous thromboembolism in nonsurgical patients: a systematic review and meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 90-98.	2.1	9
227	Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. <i>Lancet Haematology,the</i> , 2016, 3, e228-e236.	4.6	55
228	Major Bleeding and Case Fatality Rate with the Direct Oral Anticoagulants in Orthopedic Surgery: A Systematic Review and Meta-Analysis. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 042-054.	2.7	18
229	Treating patients with cancer and acute venous thromboembolism. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 535-543.	1.8	2
230	Subgroup Analysis of Patients with Cancer in Xalia - a Non-Interventional Study of Rivaroxaban in Routine Treatment of Deep Vein Thrombosis. <i>Blood</i> , 2016, 128, 1438-1438.	1.4	2
231	Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1010-1018.	3.8	77
232	The role of thrombolytic therapy in pulmonary embolism. <i>Blood</i> , 2015, 125, 2191-2199.	1.4	47
233	Small clots with large impact. <i>Blood</i> , 2015, 126, 926-927.	1.4	2
234	Epidemiology and pathophysiology of venous thromboembolism: similarities with atherothrombosis and the role of inflammation. <i>Thrombosis and Haemostasis</i> , 2015, 113, 1176-1183.	3.4	101

#	ARTICLE	IF	CITATIONS
235	Rivaroxaban: An Evaluation of its Cardiovascular Benefitâ€“Risk Profile Across Indications Based on Numbers Needed to Treat or Harm, and on Clinically Meaningful Endpoint Comparisons. <i>Drugs in R and D</i> , 2015, 15, 295-306.	2.2	0
236	Benefitâ€“risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2015, 113, 231-246.	3.4	40
237	Venous thromboembolism: â€œan ounce of prevention is worth a pound of cureâ€. <i>Thrombosis and Haemostasis</i> , 2015, 113, 1174-1175.	3.4	0
238	Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-7.	1.5	11
239	Non-vitamin K oral anticoagulants in patients with pulmonary embolism: a systematic review and meta-analysis of the literature. <i>Internal and Emergency Medicine</i> , 2015, 10, 507-514.	2.0	20
240	Statin use and bleeding risk during vitamin K antagonist treatment for venous thromboembolism: a multicenter retrospective cohort study. <i>Haematologica</i> , 2015, 100, e295-8.	3.5	3
241	Managing unusual presentations of venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 304-310.	2.1	6
242	Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation. <i>Stroke</i> , 2015, 46, 2175-2182.	2.0	213
243	The Wells rule is not accurate in hospitalized patients. <i>Nature Reviews Cardiology</i> , 2015, 12, 449-450.	13.7	4
244	Long-term Clinical Outcomes of Splanchnic Vein Thrombosis. <i>JAMA Internal Medicine</i> , 2015, 175, 1474.	5.1	180
245	Pros and Cons of Vitamin K Antagonists and Nonâ€“Vitamin K Antagonist Oral Anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 178-187.	2.7	31
246	Duration of anticoagulation after venous thromboembolism in real world clinical practice. <i>Thrombosis Research</i> , 2015, 135, 666-672.	1.7	62
247	Natural anticoagulants deficiency and the risk of venous thromboembolism: a meta-analysis of observational studies. <i>Thrombosis Research</i> , 2015, 135, 923-932.	1.7	78
248	Is diabetes a hypercoagulable state? A critical appraisal. <i>Acta Diabetologica</i> , 2015, 52, 1007-1016.	2.5	44
249	Anticoagulant therapy in atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 139-141.	1.5	3
250	Chronobiology of acute aortic rupture or dissection: A systematic review and a meta-analysis of the literature. <i>Chronobiology International</i> , 2015, 32, 385-394.	2.0	55
251	Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for intracranial hemorrhage. <i>Thrombosis Research</i> , 2015, 136, 1040-1044.	1.7	29
252	Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? Yes. <i>Internal and Emergency Medicine</i> , 2015, 10, 641-645.	2.0	4

#	ARTICLE	IF	CITATIONS
253	Treatment of pulmonary embolism. <i>Presse Medicale</i> , 2015, 44, e393-e399.	1.9	1
254	Xalia, a Non-Interventional Study Comparing Rivaroxaban with Standard Anticoagulation for Initial and Long-Term Therapy in Deep Vein Thrombosis. <i>Blood</i> , 2015, 126, 894-894.	1.4	2
255	Which patients with venous thromboembolism should receive non-vitamin K antagonist oral anticoagulants? The majority. <i>Blood Transfusion</i> , 2015, 13, 181-3.	0.4	10
256	Evidence and Clinical Judgment: Vena cava filters. <i>Thrombosis and Haemostasis</i> , 2014, 111, 618-624.	3.4	12
257	A new era for venous thromboembolism prevention in medical inpatients. <i>Thrombosis and Haemostasis</i> , 2014, 112, 627-628.	3.4	5
258	Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2014, 112, 511-521.	3.4	69
259	Clinical Utility of Antithrombotic Prophylaxis in ART Procedures: An Italian Experience. <i>PLoS ONE</i> , 2014, 9, e97604.	2.5	6
260	Efficacy and safety of patent foramen ovale closure in patients with a cryptogenic stroke: Systematic review and meta-analysis. <i>Thrombosis and Haemostasis</i> , 2014, 111, 773-776.	3.4	2
261	ABO Blood Group and Vascular Disease: An Update. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 049-059.	2.7	67
262	Antithrombotic Treatment of Splanchnic Vein Thrombosis: Results of an International Registry. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 099-105.	2.7	39
263	Management of incidental splanchnic vein thrombosis in cancer patients. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 318-320.	2.5	8
264	How can we improve the diagnosis of deep vein thrombosis and pulmonary embolism at the primary level?. <i>Clinical Practice (London, England)</i> , 2014, 11, 131-134.	0.1	0
265	Warfarin Interactions With Antibiotics in the Ambulatory Care Setting. <i>JAMA Internal Medicine</i> , 2014, 174, 409.	5.1	44
266	Association Between the Metabolic Syndrome, Its Individual Components, and Unprovoked Venous Thromboembolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 2478-2485.	2.4	48
267	Mild Antithrombin Deficiency and Risk of Recurrent Venous Thromboembolism. <i>Circulation</i> , 2014, 129, 497-503.	1.6	38
268	Association between ABCG2 and ABCB1 genes and warfarin stability: A case-control study. <i>Thrombosis Research</i> , 2014, 134, 1359-1362.	1.7	4
269	Cerebral venous thrombosis and myeloproliferative neoplasms: Results from two large databases. <i>Thrombosis Research</i> , 2014, 134, 41-43.	1.7	47
270	Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria phenotype in patients with splanchnic vein thrombosis. <i>Thrombosis Research</i> , 2014, 133, 1052-1055.	1.7	17

#	ARTICLE	IF	CITATIONS
271	Association Between In-Hospital Mortality and Renal Dysfunction in 186 219 Patients Hospitalized for Acute Stroke in the Emilia-Romagna Region of Italy. <i>Angiology</i> , 2014, 65, 906-910.	1.8	27
272	Optimal Duration of Low Molecular Weight Heparin for the Treatment of Cancer-Related Deep Vein Thrombosis: The Cancer-DACUS Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 3607-3612.	1.6	91
273	XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis. <i>Thrombosis Journal</i> , 2014, 12, 16.	2.1	27
274	Unsuspected pulmonary embolism in cancer patients: a narrative review with pooled data. <i>Internal and Emergency Medicine</i> , 2014, 9, 375-384.	2.0	17
275	Thromboprophylaxis in Acutely Ill Medical Patients: Results of A Survey Among Italian Physicians. <i>Thrombosis Research</i> , 2014, 134, 572-577.	1.7	5
276	2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2014, 35, 3033-3080.	2.2	2,591
277	Role of ABO blood group and of other risk factors on the presence of residual vein obstruction after deep-vein thrombosis. <i>Thrombosis Research</i> , 2014, 134, 264-267.	1.7	12
278	The role of inherited thrombophilia in patients with isolated pulmonary embolism: A systematic review and a meta-analysis of the literature. <i>Thrombosis Research</i> , 2014, 134, 84-89.	1.7	12
279	Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis. <i>Thrombosis and Haemostasis</i> , 2014, 111, 172-179.	3.4	97
280	Risk factors for suboptimal efficacy of 3-factor prothrombin complex concentrates in emergency VKA anticoagulation reversal. <i>Thrombosis and Haemostasis</i> , 2014, 112, 621-623.	3.4	2
281	How I treat splanchnic vein thrombosis. <i>Blood</i> , 2014, 124, 3685-3691.	1.4	71
282	Prevention of venous thromboembolism in acutely ill medical patients after the results of recent trials with the new oral anticoagulants. <i>Internal and Emergency Medicine</i> , 2013, 8, 667-672.	2.0	6
283	In-hospital mortality for pulmonary embolism: relationship with chronic kidney disease and end-stage renal disease. The hospital admission and discharge database of the Emilia Romagna region of Italy. <i>Internal and Emergency Medicine</i> , 2013, 8, 735-740.	2.0	30
284	Evaluation of right ventricular function in patients with a previous episode of pulmonary embolism using tissue Doppler imaging. <i>Internal and Emergency Medicine</i> , 2013, 8, 689-694.	2.0	4
285	Prevalence of risk factors for venous thromboembolism in the Italian population: results of a cross-sectional study from the Master Registry. <i>Internal and Emergency Medicine</i> , 2013, 8, 575-580.	2.0	11
286	Novel oral anticoagulants for the prevention of venous thromboembolism in surgical patients. <i>Thrombosis Research</i> , 2013, 131, S67-S70.	1.7	4
287	Nonadherence with INR Monitoring and Anticoagulant Complications. <i>Thrombosis Research</i> , 2013, 132, e124-e130.	1.7	29
288	Optimal treatment duration of venous thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 151-160.	3.8	16

#	ARTICLE	IF	CITATIONS
289	Certoparin for the treatment and prevention of thrombosis: pharmacological profile and results from clinical studies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 901-909.	3.3	3
290	Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes. <i>Thrombosis Research</i> , 2013, 132, 770-775.	1.7	37
291	Incidence and diagnosis of pulmonary embolism in Northern Italy: A population-based study. <i>European Journal of Internal Medicine</i> , 2013, 24, e77-e78.	2.2	9
292	Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 270-281.	3.8	88
293	Clinical management of rivaroxaban-treated patients. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 655-667.	1.8	19
294	Real-world economic burden of venous thromboembolism and antithrombotic prophylaxis in medical inpatients. <i>Thrombosis Research</i> , 2013, 131, 17-23.	1.7	25
295	Gender differences of bleeding and stroke risk in very Old atrial fibrillation patients on VKA treatment. <i>Thrombosis Research</i> , 2013, 131, 12-16.	1.7	36
296	Statin treatment and the risk of recurrent pulmonary embolism. <i>European Heart Journal</i> , 2013, 34, 1800-1806.	2.2	83
297	Relationship between ABO Blood Group and Hemorrhage: A Systematic Literature Review and Meta-Analysis. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 072-082.	2.7	67
298	Diagnostic accuracy of lung ultrasound for pulmonary embolism: a systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1269-1278.	3.8	94
299	Patient selection for thromboprophylaxis in medical inpatients. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1639-1647.	1.5	2
300	Antithrombin levels and the risk of a first episode of venous thromboembolism. A case-control study. <i>Thrombosis and Haemostasis</i> , 2013, 109, 167-169.	3.4	25
301	The role of the metabolic syndrome in patients with provoked venous thromboembolic events. <i>Thrombosis and Haemostasis</i> , 2013, 109, 759-761.	3.4	6
302	Should alcohol be considered a minor protective factor for unprovoked venous thromboembolism?. <i>Thrombosis and Haemostasis</i> , 2013, 110, 02-03.	3.4	19
303	Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism after total hip replacement. <i>Thrombosis and Haemostasis</i> , 2013, 109, 1091-1098.	3.4	13
304	The short- and long-term risk of venous thromboembolism in patients with acute spinal cord injury. <i>Thrombosis and Haemostasis</i> , 2013, 109, 34-38.	3.4	42
305	Location of venous thrombosis in patients with FVL or prothrombin G20210A mutations: Systematic review and meta-analysis. <i>Thrombosis and Haemostasis</i> , 2013, 110, 191-194.	3.4	7
306	Direct oral anticoagulants for secondary prevention in patients with non-valvular atrial fibrillation. <i>Italian Journal of Medicine</i> , 2013, 7, 8.	0.3	3

#	ARTICLE	IF	CITATIONS
307	Analysis Of Warfarin Drug-Drug Interactions With Antibiotics In The Ambulatory Care Setting. Blood, 2013, 122, 1143-1143.	1.4	1
308	Thromboprophylaxis in Surgical and Medical Patients. Seminars in Respiratory and Critical Care Medicine, 2012, 33, 163-175.	2.1	22
309	Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients. Thrombosis and Haemostasis, 2012, 107, 1027-1034.	3.4	25
310	Venous and Arterial Thrombosis Associated with HIV Infection. Seminars in Thrombosis and Hemostasis, 2012, 38, 524-529.	2.7	8
311	Non-O Blood Type Is the Commonest Genetic Risk Factor for VTE: Results from a Meta-Analysis of the Literature. Seminars in Thrombosis and Hemostasis, 2012, 38, 535-548.	2.7	195
312	Efficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation. Circulation, 2012, 126, 2381-2391.	1.6	359
313	Response to Letter Regarding Article, "Bleeding Risk in Very Old Patients on Vitamin K Antagonist Treatment: Results of a Prospective Collaborative Study on Elderly Patients Followed by Italian Centres for Anticoagulation". Circulation, 2012, 125, .	1.6	1
314	Aspirin for Preventing the Recurrence of Venous Thromboembolism. Obstetrical and Gynecological Survey, 2012, 67, 783-785.	0.4	2
315	Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists. Thrombosis and Haemostasis, 2012, 107, 1100-1106.	3.4	30
316	Steps toward simplifying the treatment of pulmonary embolism. Clinical Practice (London, England), 2012, 9, 659-667.	0.1	0
317	Splanchnic vein thrombosis: new risk factors and management. Thrombosis Research, 2012, 129, S93-S96.	1.7	19
318	Efficacia e sicurezza dei nuovi farmaci anticoagulanti orali rispetto al warfarin nella profilassi cardioembolica del paziente con fibrillazione atriale non valvolare. PiA ¹ luci che ombre. Italian Journal of Medicine, 2012, 6, 153-169.	0.3	0
319	Interventional treatment of venous thromboembolism: A review. Thrombosis Research, 2012, 129, 418-425.	1.7	46
320	The effect of subclinical hypothyroidism on vitamin K antagonist treatment. Thrombosis Research, 2012, 129, 520-522.	1.7	3
321	Management of Bleeding in Patients Receiving Conventional or New Anticoagulants. Drugs, 2012, 72, 1965-1975.	10.9	11
322	Long-term death and recurrence in patients with acute venous thromboembolism: The MASTER registry. Thrombosis Research, 2012, 130, 369-373.	1.7	33
323	Statins are better than fibrates in patients with a previous venous thromboembolism. Thrombosis Research, 2012, 130, 831-832.	1.7	0
324	Clinical approach to splanchnic vein thrombosis: Risk factors and treatment. Thrombosis Research, 2012, 130, S1-S3.	1.7	54

#	ARTICLE	IF	CITATIONS
325	Risk of Thromboembolism, Recurrent Hemorrhage, and Death After Warfarin Therapy Interruption for Gastrointestinal Tract Bleeding. <i>Archives of Internal Medicine</i> , 2012, 172, 1484.	3.8	202
326	Do medical patients need to receive pharmacologic prophylaxis for the prevention of venous thromboembolism?. <i>Internal and Emergency Medicine</i> , 2012, 7, 189-192.	2.0	5
327	Statins for Acute Ischemic Stroke. <i>Stroke</i> , 2012, 43, .	2.0	5
328	Pharmacological Prophylaxis of Venous Thromboembolism During Acute Phase of Spontaneous Intracerebral Hemorrhage. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2012, 18, 393-402.	1.7	19
329	Should the commonly accepted definition of "unprovoked venous thromboembolism" be revisited?. <i>Thrombosis and Haemostasis</i> , 2012, 107, 806-807.	3.4	6
330	Aspirin for Preventing the Recurrence of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2012, 366, 1959-1967.	27.0	545
331	Oral Anticoagulant Therapy. <i>Chest</i> , 2012, 141, e44S-e88S.	0.8	1,323
332	The negative predictive value of D-dimer on the risk of recurrent venous thromboembolism in patients with multiple previous events: A prospective cohort study (the PROLONG PLUS study). <i>American Journal of Hematology</i> , 2012, 87, 713-715.	4.1	8
333	Venous Ischemic Syndromes. <i>Frontiers of Neurology and Neuroscience</i> , 2012, 30, 191-194.	2.8	3
334	Retrievable vena cava filters: a clinical review. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 33, 258-266.	2.1	31
335	D-dimer testing in the diagnosis of cerebral vein thrombosis: a systematic review and a meta-analysis of the literature. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 582-589.	3.8	94
336	Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1297-1302.	3.8	129
337	Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normalized ratio: A prospective multicenter cohort study. <i>American Journal of Hematology</i> , 2012, 87, 384-387.	4.1	25
338	Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update. <i>Internal and Emergency Medicine</i> , 2012, 7, 9-13.	2.0	32
339	Antithrombotic Treatment of Splanchnic Vein Thrombosis: Results of an International Registry. <i>Blood</i> , 2012, 120, 499-499.	1.4	3
340	Bleeding Risk in Very Old Patients on Vitamin K Antagonist Treatment. <i>Circulation</i> , 2011, 124, 824-829.	1.6	188
341	Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. <i>Thrombosis and Haemostasis</i> , 2011, 106, 429-438.	3.4	295
342	Statins for acute ischemic stroke. <i>The Cochrane Library</i> , 2011, , CD007551.	2.8	20

#	ARTICLE	IF	CITATIONS
343	Retinal-Vein Occlusion. <i>New England Journal of Medicine</i> , 2011, 364, 979-979.	27.0	3
344	Winter and venous thromboembolism: a dangerous liaison?. <i>Future Cardiology</i> , 2011, 7, 717-719.	1.2	6
345	Venous thrombosis at unusual site in women. <i>Thrombosis Research</i> , 2011, 127, S86-S88.	1.7	7
346	Unusual Site Thrombosis. <i>Seminars in Hematology</i> , 2011, 48, 264-270.	3.4	9
347	New insights on the role of direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery. <i>Thrombosis and Haemostasis</i> , 2011, 105, 571-573.	3.4	1
348	Seasonal and monthly variability in the incidence of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2011, 106, 439-447.	3.4	79
349	Use of statins and recurrence of atrial fibrillation after catheter ablation or electrical cardioversion. <i>Thrombosis and Haemostasis</i> , 2011, 106, 363-370.	3.4	27
350	Higher mortality rate in patients hospitalised for acute pulmonary embolism during weekends. <i>Thrombosis and Haemostasis</i> , 2011, 106, 83-89.	3.4	31
351	Neutrophils and clinical outcomes in patients with acute coronary syndromes and/or cardiac revascularisation. <i>Thrombosis and Haemostasis</i> , 2011, 106, 591-599.	3.4	185
352	Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 495-505.	4.1	7
353	Prognostic relevance of an asymptomatic venous thromboembolism in patients with cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1081-1083.	3.8	63
354	Brand Name versus Generic Warfarin: A Systematic Review of the Literature. <i>Pharmacotherapy</i> , 2011, 31, 386-393.	2.6	46
355	Which patients with unprovoked VTE should receive extended anticoagulation? the minority. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 31, 301-305.	2.1	5
356	Direct thrombin and factor Xa inhibitors in children: a quest for new anticoagulants for children. <i>Wiener Medizinische Wochenschrift</i> , 2011, 161, 73-79.	1.1	6
357	Atypical case of acute coronary syndrome due to coronary-pulmonary steal syndrome secondary to pulmonary embolism. <i>Internal and Emergency Medicine</i> , 2011, 6, 349-352.	2.0	2
358	Retinal vein occlusion: time for action has come. <i>Internal and Emergency Medicine</i> , 2011, 6, 293-295.	2.0	0
359	Fondaparinux for the treatment of superficial vein thrombosis in the legs: the CALISTO study. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 835-837.	1.8	6
360	Risk of Recurrent Cerebrovascular Events in Patients with Cryptogenic Stroke or Transient Ischemic Attack and Patent Foramen Ovale: The FORI (Foramen Ovale Registro Italiano) Study. <i>Cerebrovascular Diseases</i> , 2011, 31, 109-116.	1.7	43

#	ARTICLE	IF	CITATIONS
361	Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-Extension study). <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 841-844.	1.5	111
362	Aspirin After Oral Anticoagulants for Prevention of Recurrence in Patients with Unprovoked Venous Thromboembolism. the Warfasa STUDY. <i>Blood</i> , 2011, 118, 543-543.	1.4	4
363	Emergency reversal of anticoagulation with a three-factor prothrombin complex concentrate in patients with intracranial haemorrhage. <i>Blood Transfusion</i> , 2011, 9, 148-55.	0.4	59
364	The new oral anticoagulants, do they change the benefit vs. risk for thromboprophylaxis in association to ambulatory surgery?. <i>Current Opinion in Anaesthesiology</i> , 2010, 23, 722-725.	2.0	4
365	Residual Vein Thrombosis and D-Dimer for Optimizing Duration of Anticoagulation in Idiopathic Deep Vein Thrombosis. <i>Current Pharmaceutical Design</i> , 2010, 16, 3483-3486.	1.9	4
366	Safety of thrombolysis in cerebral venous thrombosis. <i>Thrombosis and Haemostasis</i> , 2010, 104, 1055-1062.	3.4	82
367	Evidence and clinical judgment: Treatment of cerebral vein thrombosis. <i>Thrombosis and Haemostasis</i> , 2010, 103, 1109-1115.	3.4	17
368	Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis. <i>Internal and Emergency Medicine</i> , 2010, 5, 33-40.	2.0	14
369	Cerebral vein thrombosis. <i>Internal and Emergency Medicine</i> , 2010, 5, 27-32.	2.0	20
370	Unmet clinical needs in the management of patients with splanchnic vein thrombosis. <i>Internal and Emergency Medicine</i> , 2010, 5, 459-461.	2.0	1
371	Incidence of arterial cardiovascular events after venous thromboembolism: a systematic review and a meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 891-897.	3.8	76
372	Recent advances in the management of venous thromboembolism. <i>The Korean Journal of Hematology</i> , 2010, 45, 8.	0.7	11
373	Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10. <i>Thrombosis and Haemostasis</i> , 2010, 104, 118-121.	3.4	34
374	Incidence and predictors of venous thromboembolism in post-acute care patients. <i>Thrombosis and Haemostasis</i> , 2010, 104, 734-740.	3.4	14
375	Antithrombotic and fibrinolytic drugs for retinal vein occlusion: A systematic review and a call for action. <i>Thrombosis and Haemostasis</i> , 2010, 103, 271-276.	3.4	53
376	Gender Differences in Patients with Acute Ischemic Stroke. <i>Women's Health</i> , 2010, 6, 51-57.	1.5	54
377	Treatment options for deep vein thrombosis. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1069-1075.	1.8	1
378	Statins, fibrates, and venous thromboembolism: a meta-analysis. <i>European Heart Journal</i> , 2010, 31, 1248-1256.	2.2	90

#	ARTICLE	IF	CITATIONS
379	Managing Bleeding Complications in Patients Treated with the Old and the New Anticoagulants. <i>Current Pharmaceutical Design</i> , 2010, 16, 3478-3482.	1.9	9
380	Low molecular weight heparin for the treatment of retinal vein occlusion: a systematic review and meta-analysis of randomized trials. <i>Haematologica</i> , 2010, 95, 1587-1593.	3.5	46
381	Oral Xa Inhibitors. <i>Hematology/Oncology Clinics of North America</i> , 2010, 24, 727-737.	2.2	6
382	Parnaparin versus aspirin in the treatment of retinal vein occlusion. A randomized, double blind, controlled study. <i>Thrombosis Research</i> , 2010, 125, 137-141.	1.7	38
383	Diagnosis and management of venous thromboembolism: Results of a survey on current clinical practice. <i>Thrombosis Research</i> , 2010, 125, 134-136.	1.7	21
384	Prevalence and Clinical History of Incidental, Asymptomatic Pulmonary Embolism: A Meta-Analysis. <i>Thrombosis Research</i> , 2010, 125, 518-522.	1.7	189
385	Risk factors for cerebral ischemic events in patients with atrial fibrillation on warfarin for stroke prevention. <i>Atherosclerosis</i> , 2010, 212, 564-566.	0.8	37
386	Practical management of coagulopathy associated with warfarin. <i>BMJ: British Medical Journal</i> , 2010, 340, c1813-c1813.	2.3	16
387	The Optimal Duration of Anticoagulant Therapy In Patients with Cancer-Related Deep Vein Thrombosis: The Advantage of Using Residual Vein Thrombosis (the Cancer-DACUS Study). <i>Blood</i> , 2010, 116, 190-190.	1.4	5
388	SAFETY of PROTHROMBIN COMPLEX CONCENTRATES IN PATIENTS REQUIRING RAPID REVERSAL of ANTICOAGULANT TREATMENT with the VITAMIN K ANTAGONISTS: a Systematic Review and a Meta-Analysis of the Literature.. <i>Blood</i> , 2010, 116, 1113-1113.	1.4	0
389	Statin Treatment Reduces the Incidence of Recurrent Pulmonary Embolism: a Population Based Case-Control Study. <i>Blood</i> , 2010, 116, 808-808.	1.4	0
390	The Metabolic SYNDROME and the RISK of Venous Thrombosis: RESULTS of AN Individual LEVEL Patient Meta-ANALYSIS. <i>Blood</i> , 2010, 116, 3177-3177.	1.4	0
391	Oral anticoagulant therapy in patients with mechanical heart valve and intracranial haemorrhage. <i>Thrombosis and Haemostasis</i> , 2009, 101, 290-297.	3.4	51
392	The 8th American College of Chest Physicians Guidelines “ A perspective on venous thromboembolism guidelines. <i>Thrombosis and Haemostasis</i> , 2009, 101, 31-35.	3.4	12
393	Duration of anticoagulant treatment and recurrence of venous thromboembolism in patients with and without thrombophilic abnormalities. <i>Thrombosis and Haemostasis</i> , 2009, 101, 596-598.	3.4	6
394	In-hospital symptomatic venous thromboembolism and antithrombotic prophylaxis in Internal Medicine. <i>Thrombosis and Haemostasis</i> , 2009, 101, 893-901.	3.4	38
395	Presence of residual thromboemboli at least six months after a first episode of symptomatic pulmonary embolism: Do perfusion scintigraphy and angio-computed tomography agree?. <i>Thrombosis and Haemostasis</i> , 2009, 102, 1287-1289.	3.4	16
396	Fluctuations in warfarin dose response after heart valve surgery: implications for cardiac rehabilitation. <i>Monaldi Archives for Chest Disease</i> , 2009, 72, 29-32.	0.6	0

#	ARTICLE	IF	CITATIONS
397	Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists. <i>Thrombosis and Haemostasis</i> , 2009, 102, 501-504.	3.4	58
398	Acute Hyperglycemia and Early Hemorrhagic Transformation in Ischemic Stroke. <i>Cerebrovascular Diseases</i> , 2009, 28, 119-123.	1.7	74
399	Seasonal Variation in the Occurrence of Venous Thromboembolism: Data From the MASTER Registry. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009, 15, 309-315.	1.7	35
400	Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 569-576.	1.5	14
401	Low Levels of Low-Density Lipoprotein Cholesterol Increase Hemorrhagic Transformation but Not Parenchymal Hematoma in Large Artery Atherothrombosis. <i>Stroke</i> , 2009, 40, e544; author reply e545.	2.0	8
402	The Metabolic Syndrome as a Risk Factor for Venous and Arterial Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 451-457.	2.7	57
403	Metabolic Syndrome Is Associated With Venous Thromboembolism in the Korean Population. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 311-315.	2.4	54
404	Incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2009, 137, 91-93.	0.8	17
405	Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment. <i>American Journal of Hematology</i> , 2009, 84, 584-588.	4.1	56
406	Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention. <i>American Journal of Hematology</i> , 2009, 84, 579-583.	4.1	28
407	Rivaroxaban for venous thromboembolism prevention after total knee arthroplasty: RECORD3 findings. <i>European Journal of Orthopaedic Surgery and Traumatology</i> , 2009, 19, 529-533.	1.4	0
408	Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism. <i>Internal and Emergency Medicine</i> , 2009, 4, 123-128.	2.0	25
409	Prognostic stratification of chronic heart failure in elderly population: are cardiopulmonary tests and BNP really valuable?. <i>Internal and Emergency Medicine</i> , 2009, 4, 353-354.	2.0	3
410	Brain natriuretic peptide and preclinical chronic thromboembolic pulmonary hypertension. <i>Internal and Emergency Medicine</i> , 2009, 4, 441-442.	2.0	1
411	New direct thrombin inhibitors. <i>Internal and Emergency Medicine</i> , 2009, 4, 479-484.	2.0	20
412	Incidence and predictors of bleeding or thrombosis after polypectomy in patients receiving and not receiving anticoagulation therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1982-1989.	3.8	83
413	JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia. <i>Leukemia Research</i> , 2009, 33, e212-e213.	0.8	23
414	Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism. <i>Thrombosis Research</i> , 2009, 124, 256-258.	1.7	135

#	ARTICLE	IF	CITATIONS
415	Objectives and methodology: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISST). Thrombosis Research, 2009, 124, e1-e5.	1.7	15
416	Prevention of venous thromboembolism in immobilized neurological patients: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISST). Thrombosis Research, 2009, 124, e26-e31.	1.7	20
417	Effect of carotid stenosis on the prognostic value of admission blood pressure in patients with acute ischemic stroke. Atherosclerosis, 2009, 206, 469-473.	0.8	8
418	JAK2V617F mutation for the early diagnosis of Ph ⁺ myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood, 2009, 113, 5617-5623.	1.4	162
419	Seasonal variability of venous thromboembolism. Current Opinion in Pulmonary Medicine, 2009, 15, 403-407.	2.6	20
420	Oral Vitamin K Versus Placebo to Correct Excessive Anticoagulation in Patients Receiving Warfarin. Annals of Internal Medicine, 2009, 150, 293.	3.9	132
421	Residual Thrombosis on Ultrasonography to Guide the Duration of Anticoagulation in Patients With Deep Venous Thrombosis. Annals of Internal Medicine, 2009, 150, 577.	3.9	209
422	Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood, 2009, 114, 952-956.	1.4	111
423	In-hospital symptomatic venous thromboembolism and antithrombotic prophylaxis in Internal Medicine. Findings from a multicenter, prospective study. Thrombosis and Haemostasis, 2009, 101, 893-901.	3.4	7
424	Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients. Internal and Emergency Medicine, 2008, 3, 117-122.	2.0	106
425	Is there a role for timely diagnosis and early anticoagulant treatment of portal vein thrombosis in patients with liver cirrhosis?. Internal and Emergency Medicine, 2008, 3, 195-196.	2.0	8
426	Polymorphisms of the Z protein protease inhibitor and risk of venous thromboembolism: a meta-analysis. British Journal of Haematology, 2008, 143, 284-287.	2.5	11
427	Thromboembolic Consequences of Subtherapeutic Anticoagulation in Patients Stabilized on Warfarin Therapy: The Low INR Study. Pharmacotherapy, 2008, 28, 960-967.	2.6	40
428	Incidence of venous thromboembolism in patients undergoing thoracotomy for lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2008, 135, 705-706.	0.8	67
429	Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty. New England Journal of Medicine, 2008, 358, 2776-2786.	27.0	1,219
430	The MASTER registry on venous thromboembolism: Description of the study cohort. Thrombosis Research, 2008, 121, 605-610.	1.7	79
431	Factors associated with the timing of diagnosis of venous thromboembolism: Results from the MASTER registry. Thrombosis Research, 2008, 121, 751-756.	1.7	49
432	Prevalence of renal failure and use of antithrombotic prophylaxis among medical inpatients at increased risk of venous thromboembolic events. Thrombosis Research, 2008, 123, 67-71.	1.7	17

#	ARTICLE	IF	CITATIONS
433	Prevention of in-hospital VTE: why can't we do better?. <i>Lancet, The</i> , 2008, 371, 361-362.	13.7	36
434	Cardiovascular Risk Factors and Venous Thromboembolism. <i>Circulation</i> , 2008, 117, 93-102.	1.6	833
435	Statins and Secondary Prevention of Ischemic and Hemorrhagic Stroke. <i>Stroke</i> , 2008, 39, e113; author reply e114.	2.0	2
436	Acute myeloid leukemia with associated translocation t(15;17) and 11q23/MLL abnormality. <i>Leukemia and Lymphoma</i> , 2008, 49, 592-595.	1.3	4
437	Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. <i>Haematologica</i> , 2008, 93, 273-278.	3.5	123
438	An unusual case of cerebral vein thrombosis in a patient with giant cell arteritis. <i>Thrombosis and Haemostasis</i> , 2008, 100, 513-514.	3.4	5
439	Early Hemorrhagic Transformation of Brain Infarction: Rate, Predictive Factors, and Influence on Clinical Outcome. <i>Stroke</i> , 2008, 39, 2249-2256.	2.0	416
440	Inherited thrombophilic abnormalities and risk of portal vein thrombosis. <i>Thrombosis and Haemostasis</i> , 2008, 99, 675-682.	3.4	86
441	Risk factors for venous thromboembolism in the elderly: results of the master registry. <i>Blood Coagulation and Fibrinolysis</i> , 2008, 19, 663-667.	1.0	25
442	Venous thromboembolism and arterial thromboembolism. Many similarities, far beyond thrombosis per se. <i>Thrombosis and Haemostasis</i> , 2008, 100, 181-183.	3.4	20
443	Prevention of venous thromboembolism after acute spinal cord injury with low-dose heparin or low-molecular-weight heparin. <i>Thrombosis and Haemostasis</i> , 2008, 99, 978-980.	3.4	15
444	A commentary: To screen for calf DVT or not to screen? The highly variable practice among Italian centers highlights this important and still unresolved clinical option. Results from the Italian MASTER registry. <i>Thrombosis and Haemostasis</i> , 2008, 99, 241-244.	3.4	18
445	Venous thromboembolism and arterial thromboembolism. Many similarities, far beyond thrombosis per se. <i>Thrombosis and Haemostasis</i> , 2008, 100, 181-3.	3.4	11
446	Venous Thrombosis at Unusual Sites and the Role of Thrombophilia. <i>Seminars in Thrombosis and Hemostasis</i> , 2007, 33, 582-587.	2.7	23
447	The metabolic syndrome and the risk of thrombosis. <i>Haematologica</i> , 2007, 92, 297-299.	3.5	28
448	Subclinical hypothyroidism and deep venous thrombosis. <i>Thrombosis and Haemostasis</i> , 2007, 97, 803-806.	3.4	32
449	Venous and arterial thrombosis in patients with HIV infection. <i>Blood Coagulation and Fibrinolysis</i> , 2007, 18, 259-263.	1.0	16
450	Recurrent deep venous thrombosis during optimal anticoagulation and overt hyperthyroidism: a case report. <i>Blood Coagulation and Fibrinolysis</i> , 2007, 18, 801-803.	1.0	7

#	ARTICLE	IF	CITATIONS
451	Recombinant Activated Factor VII as a General Haemostatic Agent: Evidence-Based Efficacy and Safety. <i>Current Drug Safety</i> , 2007, 2, 155-161.	0.6	11
452	Natural history of cerebral vein thrombosis. <i>Current Opinion in Pulmonary Medicine</i> , 2007, 13, 372-376.	2.6	16
453	Metabolic syndrome as a risk factor for deep vein thrombosis after acute cardiac conditions. <i>Thrombosis Research</i> , 2007, 120, 815-818.	1.7	13
454	Metabolic syndrome and hyperhomocysteinemia in patients with deep vein thrombosis: a case-control study. <i>Haematologica</i> , 2007, 92, 1293-1294.	3.5	3
455	Misuse of antithrombotic therapy in atrial fibrillation patients: frequent, pervasive and persistent. <i>Journal of Thrombosis and Thrombolysis</i> , 2007, 23, 65-71.	2.1	32
456	The coagulation system in endocrine disorders: A narrative review. <i>Internal and Emergency Medicine</i> , 2007, 2, 76-83.	2.0	53
457	Rivaroxaban - An Oral, Direct Factor Xa Inhibitor - for Thromboprophylaxis after Total Knee Arthroplasty: The RECORD3 Trial. <i>Blood</i> , 2007, 110, 308-308.	1.4	6
458	Retrievable vena cava filters: clinical experience. <i>Current Opinion in Internal Medicine</i> , 2006, 5, 617-622.	1.5	5
459	Incidence of Chronic Thromboembolic Pulmonary Hypertension After a First Episode of Pulmonary Embolism. <i>Chest</i> , 2006, 130, 172-175.	0.8	377
460	Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis. <i>Blood</i> , 2006, 107, 2766-2773.	1.4	227
461	Natural history of cerebral vein thrombosis: a systematic review. <i>Blood</i> , 2006, 108, 1129-1134.	1.4	202
462	Retrievable vena cava filters: a review. <i>Current Opinion in Hematology</i> , 2006, 13, 351-356.	2.5	37
463	D-dimer is not a long-term prognostic marker following acute cerebral ischemia. <i>Blood Coagulation and Fibrinolysis</i> , 2006, 17, 303-306.	1.0	27
464	Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1853-1863.	3.8	126
465	The metabolic syndrome and the risk of venous thrombosis: a case-control study. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1914-1918.	3.8	144
466	Prophylaxis and treatment of venous thromboembolism in patients with cancer. <i>Internal and Emergency Medicine</i> , 2006, 1, 260-262.	2.0	3
467	What is the next step in D-dimer research? Education of physicians. <i>Internal and Emergency Medicine</i> , 2006, 1, 165-165.	2.0	3
468	Epidemiology and Risk Factors of Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 651-658.	2.7	114

#	ARTICLE	IF	CITATIONS
469	The Wells rule was not useful in ruling out deep venous thrombosis in a primary care setting. Evidence-Based Medicine, 2006, 11, 57-57.	0.6	1
470	Pharmacological thromboprophylaxis in acutely ill medical patients: some work remains to be done. Revista Da Associação Médica Brasileira, 2006, 52, 376-377.	0.7	0
471	Clinical experience with retrievable vena cava filters: results of a prospective observational multicenter study. Journal of Thrombosis and Haemostasis, 2005, 3, 1370-1375.	3.8	111
472	Update on the diagnosis and management of pulmonary embolism. British Journal of Haematology, 2005, 131, 301-312.	2.5	18
473	Clinical trials of deep vein thrombosis prophylaxis in medical patients. Clinical Cornerstone, 2005, 7, 16-22.	0.7	5
474	Residual venous obstruction in patients with a single episode of deep vein thrombosis and in patients with recurrent deep vein thrombosis. Thrombosis and Haemostasis, 2005, 94, 93-95.	3.4	18
475	D-Dimer Testing in Ischemic Stroke and Cerebral Sinus and Venous Thrombosis. Seminars in Vascular Medicine, 2005, 05, 379-386.	2.1	11
476	Enoxaparin for the Prevention of Venous Thromboembolism Associated With Central Vein Catheter: A Double-Blind, Placebo-Controlled, Randomized Study in Cancer Patients. Journal of Clinical Oncology, 2005, 23, 4057-4062.	1.6	293
477	A Survey of Thromboprophylaxis Management in Patients with Major Trauma. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2005, 34, 249-254.	0.3	19
478	A prospective study on cardiovascular events after acute pulmonary embolism. European Heart Journal, 2005, 26, 77-83.	2.2	168
479	What's New for DVT Prophylaxis for the Medically Ill. Disease-a-Month, 2005, 51, 194-199.	1.1	2
480	Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment. Thrombosis Research, 2005, 116, 301-306.	1.7	52
481	Tailoring warfarin induction doses to reflect individual and disease-specific factors. American Journal of Medicine, 2005, 118, 143-144.	1.5	9
482	A Randomized Trial Comparing 1 mg of Oral Vitamin K With No Treatment in the Management of Warfarin-Associated Coagulopathy in Patients With Mechanical Heart Valves. Journal of the American College of Cardiology, 2005, 46, 732-733.	2.8	38
483	Home-treatment of deep vein thrombosis in patients with cancer. Haematologica, 2005, 90, 220-4.	3.5	38
484	The safety of antithrombotic therapy during pregnancy. Expert Opinion on Drug Safety, 2004, 3, 113-118.	2.4	26
485	Perioperative Anticoagulation for Patients with Mechanical Heart Valves: A Survey of Current Practice. Journal of Thrombosis and Thrombolysis, 2004, 18, 199-203.	2.1	19
486	Managing oral anticoagulant therapy in patients with mechanical heart valves undergoing elective surgery. Blood Coagulation and Fibrinolysis, 2004, 15, 623-628.	1.0	12

#	ARTICLE	IF	CITATIONS
487	Prevalence and prevention of venous thromboembolism in patients with acute exacerbations of COPD. <i>Thrombosis Research</i> , 2003, 112, 203-207.	1.7	70
488	Weight gain after acute deep venous thrombosis: a prospective observational study. <i>Thrombosis Research</i> , 2003, 109, 31-35.	1.7	11
489	Extended Oral Anticoagulant Therapy after a First Episode of Pulmonary Embolism. <i>Annals of Internal Medicine</i> , 2003, 139, 19.	3.9	344
490	The initial phase of oral anticoagulation with warfarin in outpatients with deep venous thrombosis. <i>Blood Coagulation and Fibrinolysis</i> , 2003, 14, 11-14.	1.0	7
491	Body mass index is associated with the development of the post-thrombotic syndrome. <i>Thrombosis and Haemostasis</i> , 2003, 89, 305-9.	3.4	21
492	Oral Vitamin K Lowers the International Normalized Ratio More Rapidly Than Subcutaneous Vitamin K in the Treatment of Warfarin-Associated Coagulopathy. <i>Annals of Internal Medicine</i> , 2002, 137, 251.	3.9	147
493	Plasma Measurement of D-Dimer Levels for the Early Diagnosis of Ischemic Stroke Subtypes. <i>Archives of Internal Medicine</i> , 2002, 162, 2589.	3.8	111
494	Treatment of venous thromboembolism. <i>International Journal of Hematology</i> , 2002, 76, 40-43.	1.6	2
495	New advances in the management of acute coronary syndromes: 4. Low-molecular-weight heparins. <i>Cmaj</i> , 2002, 166, 919-24.	2.0	2
496	Selecting patients for home treatment of deep vein thrombosis: the problem of cancer. <i>Haematologica</i> , 2002, 87, 286-91.	3.5	22
497	Thrombosis prophylaxis in medical patients: a retrospective review of clinical practice patterns. <i>Haematologica</i> , 2002, 87, 746-50; discussion 250.	3.5	91
498	Deep venous thrombosis in the medically ill. <i>Psychophysiology</i> , 2002, 1, 73-8.	1.1	5
499	Three Months versus One Year of Oral Anticoagulant Therapy for Idiopathic Deep Venous Thrombosis. <i>New England Journal of Medicine</i> , 2001, 345, 165-169.	27.0	567
500	Arterial indications for the low molecular weight heparins. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2001, 2, 233.	1.5	1
501	Atrial fibrillation and antithrombotic treatment in Italian hospitalized patients: a prospective, observational study. <i>Journal of Thrombosis and Thrombolysis</i> , 2001, 12, 225-230.	2.1	13
502	Comparison of a daily fixed 2.5-mg warfarin dose with a 5-mg, international normalized ratio adjusted, warfarin dose initially following heart valve replacement. <i>American Journal of Cardiology</i> , 2001, 88, 40-44.	1.6	55
503	Low-molecular-weight heparins in the treatment of venous thromboembolism. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2000, 1, 102.	1.5	4
504	A Computer Generated Induction System for Hospitalized Patients Starting on Oral Anticoagulant Therapy. <i>Thrombosis and Haemostasis</i> , 2000, 83, 849-852.	3.4	55

#	ARTICLE	IF	CITATIONS
505	Treatment of Venous Thromboembolism. Thrombosis Research, 2000, 97, V63-V72.	1.7	13
506	Exaggerated initial response to warfarin following heart valve replacement. American Journal of Cardiology, 1999, 84, 905-908.	1.6	49
507	A Randomized Comparison of a Computer-Based Dosing Program with a Manual System to Monitor Oral Anticoagulant Therapy. Thrombosis Research, 1998, 91, 237-240.	1.7	47
508	Efficacy and safety of new oral anticoagulants compared with warfarin in cardioembolic prophylaxis of patients with non valvular atrial fibrillation. More lights than shadows. Italian Journal of Medicine, 0, , .	0.3	3
509	Risk factors for venous thromboembolism and prophylaxis in medical inpatients: data from the FADOI "GEMINI" study. Italian Journal of Medicine, 0, , 23-31.	0.3	0
510	Applying EBM in Clinical Practice. , 0, , 32-36.		0